This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John T. Carey, MD; Michael M. Lederman, MD
University Hospitals of Cleveland

JAMA. 1987;258(24):3515-3516.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We have recently described our experience in treating patients with acquired immunodeficiency syndrome (AIDS) with transfer factor (TF) pooled from donors (healthy laboratory workers) and from homosexual men with serum antibodies to the human immunodeficiency virus (HIV) who had had stable lymphadenopathy for a period of more than one year. Administration of pooled TF resulted in the acquisition of skin test responses, improvement in lymphocyte blastogenesis, and increased natural killer cell activity.¹

We now report our preliminary experience using TF prepared from normal donors only.

Study.—

Transfer factor was prepared as previously described¹ from three healthy donors who had positive skin test responses to mumps and one who had positive skin test responses to both mumps and purified protein derivative. After informed consent was obtained, four patients with AIDS received weekly subcutaneous injections of 5 x 10⁸ leukocyte equivalents of TF and were evaluated . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?